Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword

A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-08, Vol.391 (8), p.770-772
Hauptverfasser:	Hsu, Charles, Konner, Jason A., Gounder, Mrinal M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Acute lymphoblastic leukemia Adult Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Cancer Cancer therapies Chemotherapy DNA Helicases - genetics DNA Methylation Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Epigenesis, Genetic - drug effects Epigenetics Female Genetics Gynecologic Oncology Gynecology Hematology Humans Immunotherapy Leukemia Lymphatic leukemia Lymphocytes T Lymphoma Magnetic resonance imaging Neoplasms, Second Primary - diagnosis Neoplasms, Second Primary - genetics Nuclear Proteins - genetics Obstetrics Oncology Oophorectomy Ovarian cancer Ovarian Neoplasms - diagnosis Ovarian Neoplasms - genetics Ovarian Neoplasms - therapy Ovariectomy Ovary - pathology Ovary - surgery Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics Rare Diseases - diagnosis Rare Diseases - genetics Rare Diseases - therapy Synthetic Lethal Mutations - drug effects Tomography Transcription Factors - genetics Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMc2407971